Expertise in
1
conditions

Dr. John W. Swisher

Intensive Care Medicine
Cherokee Health Systems
2240 Sutherland Ave Ste 103, 
Knoxville, TN 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
1
conditions
Cherokee Health Systems
2240 Sutherland Ave Ste 103, 
Knoxville, TN 

Overview

John Swisher is an Intensive Care Medicine provider practicing medicine in Knoxville, Tennessee.

Dr. Swisher is highly rated in 1 condition, according to our data. His clinical expertise encompasses Emphysema, Pulmonary Fibrosis, Heart Failure with Preserved Ejection Fraction (HFpEF), Gastrostomy, and Carotid Artery Surgery.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 8 clinical trials. Dr. Swisher is currently accepting new patients.

Specialties

Intensive Care Medicine

Licenses

Critical Care Medicine in TN

Hospital Affiliations

Fort Loudoun Medical Center
Fort Sanders Regional Medical Center
Wellmont Bristol Regional Medical Center
Leconte Medical Center
Parkwest Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Cherokee Health Systems
2240 Sutherland Ave Ste 103, Knoxville, TN 37919

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drug: Sotatercept
Study Phase: Phase 2
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

4 Total Publications

Therapeutic options for patients with pulmonary hypertension and interstitial lung disease.
Therapeutic options for patients with pulmonary hypertension and interstitial lung disease.
Journal: Therapeutic advances in respiratory disease
Published: June 21, 2025
Similar Doctors
Expertise in
5
conditions
Dr. Eric M. Weaver
Intensive Care Medicine
Expertise in
5
conditions
Dr. Eric M. Weaver
Intensive Care Medicine
Referral may be required
Before you request

Cherokee Health Systems

2240 Sutherland Ave Ste 103, 
Knoxville, TN 
 (0.1 miles away)
865-588-8831
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Weaver is an Intensive Care Medicine provider practicing medicine in Knoxville, Tennessee. Dr. Weaver is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Pulmonary Fibrosis, Emphysema, Heart Failure with Preserved Ejection Fraction (HFpEF), Gastrostomy, and Carotid Artery Surgery. Dr. Weaver is currently accepting new patients.

Expertise in
3
conditions
Dr. Varun J. Shah
Intensive Care Medicine
Expertise in
3
conditions
Dr. Varun J. Shah
Intensive Care Medicine
Referral may be required
Before you request

Parkwest Medical Center

9352 Park West Blvd, 
Knoxville, TN 
 (5.8 miles away)
865-588-8831
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Varun Shah is an Intensive Care Medicine provider practicing medicine in Knoxville, Tennessee. Dr. Shah is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Lung Nodules, Emphysema, ALK-Positive Non-Small Cell Lung Cancer, and Byssinosis. Dr. Shah is currently accepting new patients.

Expertise in
4
conditions
Dr. Shannon L. Byrd
Intensive Care Medicine
Expertise in
4
conditions
Dr. Shannon L. Byrd
Intensive Care Medicine
Referral may be required
Before you request

Office

10904 Kingston Pike Ste 102, 
Knoxville, TN 
 (8.3 miles away)
865-588-8831
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shannon Byrd is an Intensive Care Medicine provider practicing medicine in Knoxville, Tennessee. Dr. Byrd is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Lung Nodules, Emphysema, Pulmonary Fibrosis, ALK-Positive Non-Small Cell Lung Cancer, and Gastrostomy. Dr. Byrd is currently accepting new patients.

Frequently Asked Questions about Dr. John W. Swisher

How do I make an appointment with Dr. John W. Swisher?

You can book an appointment with Dr. John W. Swisher by calling their office at 865-588-8831. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John W. Swisher a top-rated expert for Emphysema?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John W. Swisher is classified as an Advanced expert for Emphysema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John W. Swisher specialize in?

While Dr. John W. Swisher is a Intensive Care Medicine, they have specific expertise in Emphysema, Pulmonary Fibrosis, and Gastrostomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Intensive Care Medicine.

Does Dr. John W. Swisher participate in research or clinical trials?

Yes. Dr. John W. Swisher has published 4 articles and abstracts on conditions like Emphysema. You can view a list of Dr. John W. Swisher's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John W. Swisher accept my insurance?

Dr. John W. Swisher accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 865-588-8831 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Swisher's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile